Having a stroke or a heart attack? Doctors could intervene through blood reperfusion, though the reperfusion process itself results in further cellular decay. This is what is known as reperfusion injury. And for Bioquark and Humai, it is a problem of which their new partnership can finally help bring an end to.
“We are both connected in our need to solve one of the major unsolved problems that has plagued the healthcare space for decades, costing hundreds of billions of dollars annually – blood reperfusion / reoxygenation injury in critical organ systems – a problem that results in more tissue damage than the initial “insult” (heart attack, stroke, etc.).”
– Ira S. Pastor, CEO of Bioquark
Bioquark is a life science company focused on the development of novel biologics for complex regeneration, disease reversion, and tissue reprogramming. Whereas Humai is a robotics company focused on developing extracorporeal bioreactor systems for live organ support. When we spoke to Bioquark’s CEO Ira S. Pastor, he told us, “the goal of this collaboration is to put our minds and resources together to find new ways to address [reperfusion injury],” using potential solutions that, according to Humai’s Head of Engineering John LaRocco, “directly builds upon research that’s been around for decades.”
Both companies have made headlines over the course of several months now for their similar goals: bringing people back from the dead. And while they’ve done a good job in getting more people interested in the topic itself, we all sit idly by, waiting…hoping…their goals will soon be met before the grim reaper begins breathing over our own shoulders. With this new partnership, the two can finally begin combating death itself using creative solutions that only the best in modern medical science and technology can provide. If anything, if we are to remain alive a hundred years from now, we can thank both of these companies and their so-called “fanciful” efforts.